Patents Assigned to Cytovac A/S
  • Publication number: 20240076616
    Abstract: Provided is a method for preparation of a composition comprising activated human CD4+ and CD8+ lymphocytes. The method entails use of allogeneic mature dendritic cells as feeder cells added at an early stage in the induction of proliferation and activation of CD4+ and CD8+ T cells. Further provided is a method for treatment of lymphopenia related diseases by infusion of the cells obtained from the present process.
    Type: Application
    Filed: January 21, 2022
    Publication date: March 7, 2024
    Applicant: Cytovac A/S
    Inventor: Alexei Kirkin
  • Publication number: 20220175900
    Abstract: Provided is a method for preparation of a composition comprising activated human CD8+ and natural killer (NK) lymphocytes. The method entails use of mature dendritic cells as feeder cells added at an early stage in CD4+ mediated activation of the CD8+ cells. Also provided is a method for treatment of cancer using the cells obtained from the process.
    Type: Application
    Filed: April 8, 2020
    Publication date: June 9, 2022
    Applicant: Cytovac A/S
    Inventors: Alexei Kirkine, Karine Dzhanzhugazyan
  • Patent number: 10023839
    Abstract: A composition for inducing an immune response in a mammal, comprises lymphoid cells in which expression of tumor antigens has been chemically induced. The tumor antigens are induced in proliferating normal lymphoid cells, especially during the log phase of proliferation. The proliferation of the normal lymphoid cells is stimulated by normal mature dendritic cells. Most conveniently, the lymphoid cells are lymphocytes, especially peripheral blood lymphocytes. The tumor antigens are typically cancer/testis antigens, which may be chemically induced by DNA demethylation. Cancer/testis antigens are expressed in a wide range of tumors, so the composition is able to raise an immune response that is effective against a wide range of tumors, despite the fact that it is derived from normal cells. The composition may be used for preparation of an anti-tumor vaccine for prophylactic or therapeutic use.
    Type: Grant
    Filed: January 3, 2008
    Date of Patent: July 17, 2018
    Assignee: Cytovac A/S
    Inventors: Alexei Kirkin, Karine Dzhandzhugazyan
  • Patent number: 9567567
    Abstract: The present invention relates to compositions and methods for producing dendritic cells and particularly to compositions and methods for producing immature dendritic cells that are immunocompetent. We describe a method of producing dendritic cells by cultivation of monocytes, characterised by at least one of: pre-treatment of a tissue culture surface with at least one of: a substantially plasma-free and serum-free pre-treatment medium, a pre-treatment medium comprising heparin, and a pre-treatment medium comprising a protein solution; adsorption of monocytes using at least one of: a substantially plasma-free and serum-free adsorption medium; cultivation of monocytes using a substantially plasma-free and serum-free cultivation medium. We also describe compositions including the dentritic cells and uses of the dentritic cells.
    Type: Grant
    Filed: August 11, 2011
    Date of Patent: February 14, 2017
    Assignee: Cytovac A/S
    Inventors: Alexei Kirkin, Karine Djandjougazian, Martin Roland Jensen
  • Publication number: 20130216584
    Abstract: The present invention relates to compositions and methods for producing dendritic cells and particularly to compositions and methods for producing immature dendritic cells that are immunocompetent. We describe a method of producing dendritic cells by cultivation of monocytes, characterised by at least one of: pre-treatment of a tissue culture surface with at least one of: a substantially plasma-free and serum-free pre-treatment medium, a pre-treatment medium comprising heparin, and a pre-treatment medium comprising a protein solution; adsorption of monocytes using at least one of: a substantially plasma-free and serum-free adsorption medium; cultivation of monocytes using a substantially plasma-free and serum-free cultivation medium. We also describe compositions including the dentritic cells and uses of the dentritic cells.
    Type: Application
    Filed: August 11, 2011
    Publication date: August 22, 2013
    Applicant: Cytovac A/S
    Inventors: Alexei Kirkin, Karine Djandjougazian, Martin Roland Jensen
  • Publication number: 20100092498
    Abstract: A composition for inducing an immune response in a mammal, comprises lymphoid cells in which expression of tumor antigens has been chemically induced. The tumor antigens are induced in proliferating normal lymphoid cells, especially during the log phase of proliferation. The proliferation of the normal lymphoid cells is stimulated by normal mature dendritic cells. Most conveniently, the lymphoid cells are lymphocytes, especially peripheral blood lymphocytes. The tumor antigens are typically cancer/testis antigens, which may be chemically induced by DNA demethylation. Cancer/testis antigens are expressed in a wide range of tumors, so the composition is able to raise an immune response that is effective against a wide range of tumors, despite the fact that it is derived from normal cells. The composition may be used for preparation of an anti-tumor vaccine for prophylactic or therapeutic use.
    Type: Application
    Filed: January 3, 2008
    Publication date: April 15, 2010
    Applicant: Cytovac A/S
    Inventors: Alexei Kirkin, Karine Dzhandzhugazyan